112 related articles for article (PubMed ID: 30362575)
1. CYLD deficiency promotes pancreatic cancer development by causing mitotic defects.
Xie S; Wu Y; Hao H; Li J; Guo S; Xie W; Li D; Zhou J; Gao J; Liu M
J Cell Physiol; 2019 Jun; 234(6):9723-9732. PubMed ID: 30362575
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppressor CYLD controls epithelial morphogenesis and homeostasis by regulating mitotic spindle behavior and adherens junction assembly.
Xie W; Yang Y; Gao S; Song T; Wu Y; Li D; Liu M; Zhou J
J Genet Genomics; 2017 Jul; 44(7):343-353. PubMed ID: 28750888
[TBL] [Abstract][Full Text] [Related]
3. CEP192 interacts physically and functionally with the K63-deubiquitinase CYLD to promote mitotic spindle assembly.
Gomez-Ferreria MA; Bashkurov M; Mullin M; Gingras AC; Pelletier L
Cell Cycle; 2012 Oct; 11(19):3555-8. PubMed ID: 22895009
[TBL] [Abstract][Full Text] [Related]
4. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Sun X; Liu M; Hao J; Li D; Luo Y; Wang X; Yang Y; Li F; Shui W; Chen Q; Zhou J
Cell Cycle; 2013 Apr; 12(7):1133-41. PubMed ID: 23470638
[TBL] [Abstract][Full Text] [Related]
5. miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD.
Sanches JGP; Xu Y; Yabasin IB; Li M; Lu Y; Xiu X; Wang L; Mao L; Shen J; Wang B; Hou L; Ju J; Zhao J; Song B
Chem Biol Interact; 2018 Apr; 285():85-95. PubMed ID: 29477382
[TBL] [Abstract][Full Text] [Related]
6. Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells.
La T; Jin L; Liu XY; Song ZH; Farrelly M; Feng YC; Yan XG; Zhang YY; Thorne RF; Zhang XD; Teng L
Oncol Res; 2020 Sep; 28(4):385-398. PubMed ID: 32252875
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway.
Xu DD; Zhou PJ; Wang Y; Zhang L; Fu WY; Ruan BB; Xu HP; Hu CZ; Tian L; Qin JH; Wang S; Wang X; Li YC; Liu QY; Ren Z; Zhang R; Wang YF
Mol Cancer; 2016 May; 15(1):40. PubMed ID: 27189061
[TBL] [Abstract][Full Text] [Related]
8. CYLD deficiency exacerbates lipopolysaccharide (LPS)-induced pyroptosis in astrocytes of mice with sepsis.
Li L; Shu MQ; Chen J
Biochem Biophys Res Commun; 2019 Jul; 514(4):1066-1073. PubMed ID: 31097224
[TBL] [Abstract][Full Text] [Related]
9. Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma.
Shinriki S; Jono H; Maeshiro M; Nakamura T; Guo J; Li JD; Ueda M; Yoshida R; Shinohara M; Nakayama H; Matsui H; Ando Y
J Pathol; 2018 Mar; 244(3):367-379. PubMed ID: 29235674
[TBL] [Abstract][Full Text] [Related]
10. Cep70 overexpression stimulates pancreatic cancer by inducing centrosome abnormality and microtubule disorganization.
Xie S; Qin J; Liu S; Zhang Y; Wang J; Shi X; Li D; Zhou J; Liu M
Sci Rep; 2016 Feb; 6():21263. PubMed ID: 26893288
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
12. CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
Haq S; Sarodaya N; Karapurkar JK; Suresh B; Jo JK; Singh V; Bae YS; Kim KS; Ramakrishna S
Cancer Lett; 2022 Jan; 525():146-157. PubMed ID: 34742871
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD.
Song H; Li D; Wu T; Xie D; Hua K; Hu J; Deng X; Ji C; Deng Y; Fang L
BMB Rep; 2018 Nov; 51(11):602-607. PubMed ID: 30269739
[TBL] [Abstract][Full Text] [Related]
14. Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.
Johari T; Maiti TK
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2081-2089. PubMed ID: 29807073
[TBL] [Abstract][Full Text] [Related]
15. Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma.
Miyake S; Miwa T; Yoneda G; Kanemaru A; Saito H; Minoda R; Orita Y; Saito H; Jono H
PLoS One; 2020; 15(10):e0240216. PubMed ID: 33031450
[TBL] [Abstract][Full Text] [Related]
16. MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression.
Zhang K; Guo L
Gene; 2018 Jan; 641():272-278. PubMed ID: 29054757
[TBL] [Abstract][Full Text] [Related]
17. Potential role for the tumor suppressor CYLD in brain and notochord development.
Li T; Wang Y; Li D; Zhou J; Zhang B; He X
Thorac Cancer; 2021 Jun; 12(12):1900-1908. PubMed ID: 33982884
[TBL] [Abstract][Full Text] [Related]
18. miR-182 controls cell growth in gastrointestinal stromal tumors by negatively regulating CYLD expression.
Ling T; Yu F; Cao H
Oncol Rep; 2018 Dec; 40(6):3705-3713. PubMed ID: 30542706
[TBL] [Abstract][Full Text] [Related]
19. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
20. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
Zhang LM; Zhou JJ; Luo CL
Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
